Ascendis Pharma A/S (ASND) Q2 2019 Results Earnings Conference Call August 28, 2019 4:30 PM ET Company Participants Jan Mikkelsen - President and Chief Executive Officer Dr. Jonathan Leff - Chief Medical Officer Scott Smith - SVP and Chief Financial Officer Tom Larson - Chief Commercial Officer Juha Punnonen - Head of Oncology Conference Call Participants Josh Schimmer - Evercore Tazeen Ahmad - Bank of America Merrill Lynch Jessica Fye - JPMorgan Michelle Gilson - Canaccord Genuity Jim Birchenough - Wells F ...

Ascendis Pharma A/S (ASND) Q1 2019 Earnings Conference Call May 30, 2019 4:30 PM ET Company Participants Scott Smith - Senior Vice President & Chief Financial Officer Jan Mikkelsen - President & Chief Executive Officer Jonathan Leff - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Jessica Fye - JPMorgan Michelle Gilson - Canaccord Genuity Adam Walsh - Stifel Alethia Young - Cantor Fitzgerald Operator Good day, ladies and gentlemen, and welcome to the First Qu ...

Ascendis Pharma A/S (ASND) Q1 2019 Earnings Conference Call April 3, 2019 4:30 PM ET Company Participants Scott Smith - SVP and CFO Jan Mikkelsen - President and CEO Jonathan Leff - SVP and Chief Medical Officer Conference Call Participants Michelle Gilson - Canaccord Genuity Yuko Oku - JP Morgan Adam Walsh - Stifel, Nicolaus & Company Liana Moussatos - Wedbush Securities Inc James Birchenough - Wells Fargo Securities Tiago Fauth - Credit Suisse Olivia Yang - Cantor Fitzgerald Joseph Schwartz - SVB Leerink ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTI ...

ascendis | pharma Ascendis Pharma A/S January 2019 1 Cautionary Note On Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our future results of operations and financial position, including our business strategy, prospective products, availability of funding, clinical trial results, product approvals and regulatory pathways, collaborations, timing and likelihoo ...